Lindsay A Renfro1, Nan Zhang2, Margarita Lopatin2, Calvin Chao2, Steven R Alberts3. 1. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN. Electronic address: renfro.lindsay@mayo.edu. 2. Genomic Health, Inc, Redwood City, CA. 3. Department of Oncology, Mayo Clinic, Rochester, MN.
Abstract
BACKGROUND: The Oncotype DX colon cancer assay is a validated predictor of recurrence risk in patients with resected stage II colon cancer. We previously reported that Oncotype DX led to a change in treatment recommendations for 45% of patients with T3 mismatch repair proficient (MMR-P) stage II tumors in a prospective study. In the present study, we report the assay's influence on patient treatment decisions, physician confidence, concordance between physicians and patients, and patient decisional conflict. PATIENTS AND METHODS: Consecutive patients with resected stage IIA colon cancer were enrolled. The tumor specimens were assessed using a 12-gene assay (reverse transcription-polymerase chain reaction) and by immunohistochemistry for MMR. Before and after receiving the results, the patients completed surveys that included their treatment preference, their current and preferred roles in treatment decision-making, and indicators of decisional conflict. Physicians completed similar pre- and postassay surveys. RESULTS: Of 221 patients enrolled, 139 T3 MMR-P patients were evaluable for the patient-reported analyses and 150 patients were evaluable for the physician-reported analyses. Before the assay, 46% of the patients chose observation, 3% 5-fluorouracil, 7% oxaliplatin, 4% other, and 41% were undecided. After the assay, 75% chose observation, 12% 5-fluorouracil, 11% oxaliplatin, and 2% other. After the assay, 94% of the defined treatment decisions were concordant between patients and physicians compared with 60% before the assay. Physicians reported the assay influenced their treatment decisions and increased confidence in their treatment recommendations for 69% and 84% of patients, respectively. Most patients (86%) reported that the assay influenced their treatment decisions. Patient decisional conflict was significantly lower after learning the assay results (P < .001). CONCLUSION: In the present prospective study, knowledge of the 12-gene assay results influenced treatment decisions for most patients and physicians, increased physician confidence, improved the concordance between patients and physicians, and decreased patient decisional conflict.
BACKGROUND: The Oncotype DX colon cancer assay is a validated predictor of recurrence risk in patients with resected stage II colon cancer. We previously reported that Oncotype DX led to a change in treatment recommendations for 45% of patients with T3 mismatch repair proficient (MMR-P) stage II tumors in a prospective study. In the present study, we report the assay's influence on patient treatment decisions, physician confidence, concordance between physicians and patients, and patient decisional conflict. PATIENTS AND METHODS: Consecutive patients with resected stage IIA colon cancer were enrolled. The tumor specimens were assessed using a 12-gene assay (reverse transcription-polymerase chain reaction) and by immunohistochemistry for MMR. Before and after receiving the results, the patients completed surveys that included their treatment preference, their current and preferred roles in treatment decision-making, and indicators of decisional conflict. Physicians completed similar pre- and postassay surveys. RESULTS: Of 221 patients enrolled, 139 T3 MMR-P patients were evaluable for the patient-reported analyses and 150 patients were evaluable for the physician-reported analyses. Before the assay, 46% of the patients chose observation, 3% 5-fluorouracil, 7% oxaliplatin, 4% other, and 41% were undecided. After the assay, 75% chose observation, 12% 5-fluorouracil, 11% oxaliplatin, and 2% other. After the assay, 94% of the defined treatment decisions were concordant between patients and physicians compared with 60% before the assay. Physicians reported the assay influenced their treatment decisions and increased confidence in their treatment recommendations for 69% and 84% of patients, respectively. Most patients (86%) reported that the assay influenced their treatment decisions. Patient decisional conflict was significantly lower after learning the assay results (P < .001). CONCLUSION: In the present prospective study, knowledge of the 12-gene assay results influenced treatment decisions for most patients and physicians, increased physician confidence, improved the concordance between patients and physicians, and decreased patient decisional conflict.
Authors: Richard G Gray; Philip Quirke; Kelly Handley; Margarita Lopatin; Laura Magill; Frederick L Baehner; Claire Beaumont; Kim M Clark-Langone; Carl N Yoshizawa; Mark Lee; Drew Watson; Steven Shak; David J Kerr Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544
Authors: Geetika Srivastava; Lindsay A Renfro; Robert J Behrens; Margarita Lopatin; Calvin Chao; Gamini S Soori; Shaker R Dakhil; Rex B Mowat; J Philip Kuebler; George Kim; Miroslaw Mazurczak; Mark Lee; Steven R Alberts Journal: Oncologist Date: 2014-04-07
Authors: Shelly S Lo; Patricia B Mumby; John Norton; Karen Rychlik; Jeffrey Smerage; Joseph Kash; Helen K Chew; Ellen R Gaynor; Daniel F Hayes; Andrew Epstein; Kathy S Albain Journal: J Clin Oncol Date: 2010-01-11 Impact factor: 44.544
Authors: Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg Journal: J Clin Oncol Date: 2004-04-05 Impact factor: 44.544
Authors: Greg Yothers; Michael J O'Connell; Mark Lee; Margarita Lopatin; Kim M Clark-Langone; Carl Millward; Soonmyung Paik; Saima Sharif; Steven Shak; Norman Wolmark Journal: J Clin Oncol Date: 2013-11-12 Impact factor: 44.544
Authors: Benjamin G Allar; Evangelos Messaris; Vitaliy Y Poylin; Benjamin L Schlechter; Thomas E Cataldo Journal: Med Oncol Date: 2022-02-12 Impact factor: 3.064
Authors: Maryam A L Eissa; Lane Lerner; Eihab Abdelfatah; Nakul Shankar; Joseph K Canner; Nesrin M Hasan; Vesal Yaghoobi; Barry Huang; Zachary Kerner; Felipe Takaesu; Christopher Wolfgang; Ruby Kwak; Michael Ruiz; Matthew Tam; Thomas R Pisanic; Christine A Iacobuzio-Donahue; Ralph H Hruban; Jin He; Tza-Huei Wang; Laura D Wood; Anup Sharma; Nita Ahuja Journal: Clin Epigenetics Date: 2019-04-05 Impact factor: 6.551